ProQR Therapeutics N.V. Quarterly Research And Development Expense in EUR from Q2 2017 to Q3 2024

Taxonomy & unit
ifrs-full: EUR
Summary
ProQR Therapeutics N.V. quarterly/annual Research And Development Expense history and growth rate from Q2 2017 to Q3 2024.
  • ProQR Therapeutics N.V. Research And Development Expense for the quarter ending September 30, 2024 was €9.41M, a 72.9% increase year-over-year.
  • ProQR Therapeutics N.V. Research And Development Expense for the twelve months ending September 30, 2024 was €33.5M, a 19.1% increase year-over-year.
  • ProQR Therapeutics N.V. annual Research And Development Expense for 2023 was €25.1M, a 50.6% decline from 2022.
  • ProQR Therapeutics N.V. annual Research And Development Expense for 2022 was €50.9M, a 20.5% increase from 2021.
  • ProQR Therapeutics N.V. annual Research And Development Expense for 2021 was €42.2M, a 10.7% increase from 2020.
Research And Development Expense, Trailing 12 Months (EUR)
Research And Development Expense, Quarterly (EUR)
Research And Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 33.5M 9.41M +3.97M +72.9% Jul 1, 2024 Sep 30, 2024 6-K 2024-11-07
Q2 2024 29.5M 7.05M +1.14M +19.3% Apr 1, 2024 Jun 30, 2024 6-K 2024-08-08
Q1 2024 28.4M 9.28M +3.22M +53.2% Jan 1, 2024 Mar 31, 2024 6-K 2024-05-09
Q4 2023 25.1M 7.73M -2.97M -27.7% Oct 1, 2023 Dec 31, 2023 20-F 2024-03-13
Q3 2023 28.1M 5.45M -9.91M -64.5% Jul 1, 2023 Sep 30, 2023 6-K 2024-11-07
Q2 2023 38M 5.91M -5.54M -48.4% Apr 1, 2023 Jun 30, 2023 6-K 2024-08-08
Q1 2023 43.6M 6.06M -7.31M -54.7% Jan 1, 2023 Mar 31, 2023 6-K 2024-05-09
Q4 2022 50.9M 10.7M -1.76M -14.1% Oct 1, 2022 Dec 31, 2022 20-F 2024-03-13
Q3 2022 52.6M 15.4M +4.23M +38% Jul 1, 2022 Sep 30, 2022 6-K 2023-11-07
Q2 2022 48.4M 11.4M +1.71M +17.6% Apr 1, 2022 Jun 30, 2022 6-K 2023-08-03
Q1 2022 46.7M 13.4M +4.46M +50.1% Jan 1, 2022 Mar 31, 2022 6-K 2023-05-16
Q4 2021 42.2M 12.5M +4.04M +48% Oct 1, 2021 Dec 31, 2021 6-K 2022-02-24
Q3 2021 38.2M 11.1M +2.82M +34% Jul 1, 2021 Sep 30, 2021 6-K 2022-11-09
Q2 2021 35.4M 9.74M +1.15M +13.4% Apr 1, 2021 Jun 30, 2021 6-K 2022-08-04
Q1 2021 34.2M 8.91M -3.92M -30.6% Jan 1, 2021 Mar 31, 2021 6-K 2022-05-05
Q4 2020 38.1M 8.42M -5.51M -39.6% Oct 1, 2020 Dec 31, 2020 6-K 2022-02-24
Q3 2020 43.6M 8.3M -2.77M -25% Jul 1, 2020 Sep 30, 2020 6-K 2021-11-04
Q2 2020 46.4M 8.59M -936K -9.83% Apr 1, 2020 Jun 30, 2020 6-K 2021-08-05
Q1 2020 47.4M 12.8M +862K +7.21% Jan 1, 2020 Mar 31, 2020 6-K 2020-05-07
Q4 2019 46.5M 13.9M Oct 1, 2019 Dec 31, 2019 6-K 2021-02-25
Q3 2019 11.1M +4.78M +75.9% Jul 1, 2019 Sep 30, 2019 6-K 2020-11-16
Q2 2019 9.52M +3.53M +59% Apr 1, 2019 Jun 30, 2019 6-K 2020-08-06
Q1 2019 12M Jan 1, 2019 Mar 31, 2019 6-K 2020-05-07
Q3 2018 6.3M Jul 1, 2018 Sep 30, 2018 6-K 2019-11-12
Q2 2018 5.99M -1.56M -20.7% Apr 1, 2018 Jun 30, 2018 6-K 2019-08-07
Q2 2017 7.55M Apr 1, 2017 Jun 30, 2017 6-K 2018-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.